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Abstract
Next-generation sequencing (NGS) has been instrumental in solving the genetic basis of rare
inherited diseases, especially neurodevelopmental syndromes. However, functional workup is
essential for precise phenotype definition and to understand the underlying disease mecha-
nisms. Using whole exome (WES) and whole genome sequencing (WGS) in four independent fam-
ilies with hypotonia, neurodevelopmental delay, facial dysmorphism, loss of white matter, and
thinning of the corpus callosum, we identified four previously unreported homozygous trun-
cating PPP1R21 alleles: c.347delT p.(Ile116Lysfs*25), c.2170_2171insGGTA p.(Ile724Argfs*8),
c.1607dupT p.(Leu536Phefs*7), c.2063delA p.(Lys688Serfs*26) and found that PPP1R21 was
absent in fibroblasts of an affected individual, supporting the allele's loss of function effect.
PPP1R21 function had not been studied except that a large scale affinity proteomics approach
suggested an interactionwith PIBF1 defective in Joubert syndrome. Our co-immunoprecipitation
studies did not confirm this but in contrast defined the localization of PPP1R21 to the early
endosome. Consistent with the subcellular expression pattern and the clinical phenotype exhibit-
ing features of storage diseases, we found patient fibroblasts exhibited a delay in clearance of
transferrin-488 while uptake was normal. In summary, we delineate a novel neurodevelopmen-
tal syndrome caused by biallelic PPP1R21 loss of function variants, and suggest a role of PPP1R21
within the endosomal sorting process or endosomematuration pathway.
K EYWORDS
early endosome, endo-lysosome, neurodevelopmental syndrome, PPP1R21, storage disease
1 BACKGROUND
Increased utilization of next-generation sequencing (NGS), such
as whole exome (WES) and whole genome sequencing (WGS) has
enabled rapid expansion of our understanding of the genetic etiology
of neurodevelopmental disease. Historically, diagnostic evaluation
consisted of phenotype-driven genetic testing; however, this approach
has limited efficacy for common and genetically heterogeneous
phenotypes like developmental delay. The increased utilization of
NGS-based testing, including exome analysis, has enabled a gene- and
variant-driven approach to diagnosis and has greatly accelerated new
syndrome and newdisease gene discovery (Boycott et al., 2017; Chong
et al., 2015).Majority of the newly recognized disease genes have been
identified in individuals with neurological disorders. The underlying
molecular mechanisms for these disorders range from gene defects
resulting in true brain malformations to causing degenerative disease.
Neurological deficits are also frequently observed with metabolic
disorders where defective lipid, mucopolysaccharide or glycoprotein
processing results in a specific subgroup of disease entities referred
to as (lysosomal) storage disorders. The common clinical features of
lysosomal storage disorders include coarse facial features and skeletal
abnormalities, enlargement of liver and spleen, neurodevelopmental
delay (mainly manifesting as neurodegenerative phenotype), lung and
heart disease as well as hearing and visual impairment. More than 50
disease entities have been described to date and although individually
very rare, together they represent a significant disease burden affect-
ing approximately 1:5,000 individuals (Fuller, Meikle, & Hopwood,
2006). Age of onset of symptoms varies from prenatally to adult
age. Inheritance patterns are mostly autosomal-recessive and rarely,
X-linked.
Lysosomes are the recycling centers of cells and degradation of
macromolecules requires a number of enzyme-driven steps within the
endosomal–autophagic–lysosomal system.Mechanistically, functional
deficits in degradation pathways cause accumulation of such material
within lysosomes as well as within the cytosol with toxic effects, even-
tually resulting in cell death.Most defective genes encode for enzymes,
however defects have also been identified in genes encoding for
proteins involved in transport processes or transmembrane proteins
(Bennett & Hofmann, 1999; Fuller et al., 2006; Parkinson-Lawrence
et al., 2010). Lysosomal degradation of cellular material can be accom-
plished via different pathways, including endosomal degradation
where late endosomes fuse with lysosomes, including transient dock-
ing for content exchange (Platt, Boland, & van der Spoel, 2012). Endo-
some maturation into late endosomes occurs after approximately 5–
10 min of fusion with novel endocytic vesicles (Maxfield, 2014). Early
endosomes (EE) serve as a focal point of the endocytic pathway where
internalized proteins and lipids are destined for recycling to the plasma
membrane, for degradation in lysosomesordelivered to the trans-Golgi
network and functional deficits have been shown to play a role in a
number of human diseases often demonstrating a neurological phe-
notype such as Alzheimer's disease, Down syndrome, Lowe syndrome,
andHuntington's disease (Jovic, Sharma, Rahajeng, & Caplan, 2010).
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Despite the progress made in recent years, substantial gaps
remain in understanding the heterogeneity of clinical phenotypes of
neurological disorders and the underlying molecular mechanisms.
Here, we report on six patients from four unrelated consanguineous
families with similar neurological phenotype. We detected homozy-
gous truncating variants in PPP1R21 (Protein Phosphatase 1, regu-
latory subunit 21) in the affected individuals by WES or WGS. In
parallel to our study, PPP1R21 loss of function alleles have been identi-
fied in three individuals with a similar syndromic neurodevelopmental
phenotype, however no functional studies to understand the under-
lying patho-mechanism and PPP1R21 protein function had been per-
formed and PPP1R21 function had remained elusive. Here, we now
suggest a role for PPP1R21 within the endo-lysosomal compartment
and propose PPP1R21 loss of function results in a mild disturbance of
endosome function.
2 METHODS
2.1 Ethics statement and family ascertainment
The study was conducted in accordance with the protocol approved
by the Institutional Review Board at the Baylor College of Medicine
in Houston, Sidra Medicine in Qatar, University of Geneva in Switzer-
land, University of Netherlands, Royal Children's Hospital, Melbourne,
Australia. Written informed consents were obtained from all live par-
ticipating individuals and parents of the minors. Patients at Baylor
Genetics laboratories in Baylor College of Medicine were referred
by physicians for clinical exome sequencing. Patients in Nijmegen
were included via the diagnostic route (innovative diagnostic pro-
gram). Inclusion criteria used in the Nijmegen part of the study were
patients with neurodevelopmental delay of likely genetic origin with
exclusion of individuals in whom previously chromosomal aberrances
were detected either by chromosome analysis or array-CGH, proven
intrauterine TORCH infections or perinatal asphyxia. Patients at Uni-
versityofGenevawere recruitedduring a researchprotocol that aimed
to identify novel autosomal recessive genes in offspring of consan-
guineous families. Patients at theRoyalChildren'sHospital,Melbourne
were recruited as part of theAustralianGenomicsAcuteCareFlagship,
which provides rapid genomic testing to infants and children admitted
to intensive care units with suspectedmonogenic conditions.
2.2 Whole exome andwhole genome sequencing
and subsequent analyses
Peripheral blood samples were collected from available members of
the four families and genomic DNA was extracted using standard
protocol. WES was performed either at Baylor Genetics Laboratories
using VCRome v3 in-solution exome probes followed by sequencing on
Illumina HiSeq 2500 instrument (Family 1, subject II-6), using kit Agi-
lent SureSelect Human All Exon v5 and sequencing on Illumina HiSeq
2500 at University of Geneva (Family 1, subject II-5), using Agilent
Sure select V6 with subsequent sequencing on a HiSeq machine at
Novogene LTD Hong Kong for Nijmegen samples (Family 3, subject
V:4) or using Agilent Sureselect QXT CREv1 kit, followed by sequenc-
ing on Illumina NextSeq500 at Victorian Clinical Genetics Services
(Family 4). Further, OmniExpress 750K array was used in Family 2 for
genome-wide homozygosity mapping using DNA from six family mem-
bers at Sidra Medical & Research Center in Qatar (Figure 1A) which
showed three regionsof homozygosity co-segregatingwith thedisease
(Supp. Figure S1). Subsequently, DNA sample from individual II-3 was
subjected to WGS to a mean coverage of 30× on the Illumina HiSeq
X platform and data was analyzed for potential pathogenic variants
within the three regions of homozygosity.
Sequencing data from each family was independently analyzed
by respective diagnostic or research laboratories. Variants with >1%
allele frequency in public SNP databases were removed from further
analysis and the remaining variants were prioritized based on genetic
evidence including variant rarity (e.g., novel variant), allele transmis-
sion (e.g., biallelic variants), predicted variant severity, and phenotype
overlap between reported genetic disorders and the patient phe-
notypes. Possible causal variants in known disease genes that could
explain patient's phenotype were not detected in any subject. To
further explore the genetic basis of disease in these families, we
investigated all rare deleterious variants that are in nondisease genes
especially homozygous variants because of consanguinity in the fam-
ilies and apparently recessive mode of inheritance (Figure 1A). Follow
up confirmation and co-segregation analyses for putative pathogenic
variants were performed using Sanger sequencing for families 1–3 fol-
lowing standard protocols. Primer sequences can be found in a supple-
mental table in the supplementalmaterial. IdentifiedPPP1R21 variants
were submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).
2.3 Immunofluorescence and cell culture studies
Immunofluorescence and cell culture analyses were performed as pre-
viously described (Schmidts et al., 2015). Briefly, IMCD3, hTERT-RPE,
SH-SY5Y cells and patient as well as control fibroblasts were cultured
inDMEM-F12mediumwith 5%FBSunder standard conditions. For cil-
iation experiments, cells were serum starved for 24 hr. Primary anti-
bodies used: Golgi marker GM130 (mouse, ab169276, Abcam, USA),
Golgi marker 58K (ab27043 mouse, Abcam, USA), early endosome
marker EEA1 (1G11 ab70521, mouse monoclonal, Abcam), PPP1R21
antibody (rabbit, HHPA036792 (ab1) and HPA 036791 (ab2), Atlas
antibodies, Sweden), acetylated tubulin (mouse monoclonal 6-11-B1,
Sigma, USA). In brief, cells were grown on coverslips, washed with PBS
and fixed 5 min in 5% PFA. After three washes, cells were permeabi-
lized using 0.1% Triton for 3 min, washed three times and incubated
in 5% BSA for 1 hr at RT to bock unspecific reactions. Incubation in
primary antibodies was then performed for 1 hr (1:200 in 5% BSA),
after five washes, cells were incubated in corresponding fluorescence
tagged secondary 1:1,000 antibody dilutions for 30 min, washed five
times in PBS and thenmounted in Vectashield with DAPI. Images were
taken with a Zeiss Apotome Axiovert 200 and processed with AxioVi-
sion 4.8 and Fiji software.
2.4 Transferrin assay
Patient fibroblasts and control fibroblasts from an age matched
healthy individual were grown under standard conditions and serum
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F IGURE 1 Biallelic pathogenic variants identified in the PPP1R21 gene. (A) Pedigrees and photographs of four families that co-segregate
homozygous truncating PPP1R21 variants with a neurodevelopmental phenotype. Filled squares and circles represent affectedmales and
females, respectively. A diagonal line across a symbol means individual is deceased. Numbers within a symbol correspond to additional same-sex
siblings. PPP1R21 genotypes of available family members are shown under their symbols. m, mutant allele;+, reference allele. (B)MRI images of
the brain of the subjects. Family numbers and individual IDs shown at the bottom of each image correspond to the pedigrees in panel A. Family 1:
Image 1; axial T2-w image showing an irregular outline to prominent bodies of both lateral ventricles with abnormal periventricular T2
hyperintensity returned from the deepwhite matter. Image 2; demonstrates generous extra-axial CSF spaces with bilateral and symmetric
underopercularization. Image 3; sagittal T1-w image showing foreshortening and thinning of an otherwise intact corpus callosum. Family 2: Image
4; axial T2-w image demonstrating slight prominence to the supratentorial ventricular systemwith increased T2 hyperintensity returned from the
bilateral posterior centra semiovale. Image 5; demonstrates irregular outline to the bodies of both lateral ventricles in addition to the increased T2
hyperintensity returned from the periventricular white matter. Image 6; sagittal T1-wmidline image again demonstrating thinning and
foreshortening to the body of the corpus callosum. Family 3: Image 7; axial T2-w image demonstrates prominence to the bodies of the lateral
ventricles with generous extra-axial CSF spaces with bilateral and symmetric underopercularization. Image 8; axial T2-w image shows a slightly
irregular outline to the bodies of both slightly prominent lateral ventricles. Image 9; sagittal T2-wmidline image demonstrates thinning and
foreshortening of the corpus callosum. Family 4: images 10–12 obtained from affected individual IV.1 showing abnormally deep and box-like
Sylvian fissures, diffuse reduction in cerebral volume, particularly the deepwhite matter signs of dysmyelination, diffuse reduction in the
brainstem and vermian volume (molar tooth sign in image 11) and dysmorphic appearance of the corpus callosum and brainstem. (C) Schematic
representation of the PPP1R21 gene, its predicted protein product, and locations of the pathogenic variants. Introns, exons, and untranslated
regions of the PPP1R21 gene are shown by a horizontal line, vertical thick bars, and thin gray bars, respectively. Exon numbering and variant
nomenclature is based on RefSeq accession number NM_NM_001135629.2 for cDNA andNP_001129101.1 for protein
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starved for 3 hr before start of the experiment. Cells were incubated
in medium containing transferrin-Alexa-Fluor-488 conjugate 1:1,000
(Invitrogen/ThermoFisher, USA) and fixed in 4%PFAafter 5, 10, and30
min of incubation. Cells were then mounted in vectashield containing
DAPI and images taken using a Zeiss Axiovert Apotome microscope.
For washout/chase, cells were repetitively washed and re-incubated
in fresh medium containing unlabeled transferrin 1:200 every 20 min
and fixed in 4% PFA after 1 and 2 hr washout/chase, mounted in
vectashield containing DAPI and images taken using a Zeiss Axiovert
Apotomemicroscope.
2.5 q-PCR
PPP1R21 mRNA-quantification in fibroblasts carrying PPP1R21
p.Leu536Phefs*7 in a homozygous manner versus fibroblasts from a
healthy control individual was performed using total RNA and q-PCR
performed using SYBR-Green (Qiagen, Germantown, USA) according
to the manufacturer‘s protocol. PPP1R21 levels were normalized to
GAPDH levels. Statistical analysiswas performedusing Student's t-test.
3 RESULTS
3.1 Clinical findings
Salient clinical features of six subjects from the four study families are
provided in Table 1 and pedigrees and clinical images shown in Fig-
ure 1. Subject II-6 fromFamily 1was born at 33weeks to a 33-year-old
G6P6 mother and 44-year-old father. Her parents are from Syria and
are first cousins. Prenatal ultrasound showed hyperechogenic bowel,
hand, and skull anomalies and the neonatal period was complicated
by respiratory distress at birth requiring surfactant application and 2
days of respiratory support. She had dysmorphic facial features, severe
central hypotonia, poor suck, weak cry, minimal vision, and esotropia.
She was noted to have feeding difficulties, constipation, distended
abdomen, and small thoracic cage. Cardiac concerns included mild
left pulmonary stenosis and secundum atrial septal defect (ASD). She
had three affected siblings with similar clinical presentation who had
died due to disease-related complications. Brain MRI of subject II-5
showed irregular outline to prominent bodies of both lateral ventricles
with abnormal periventricular T2 hyperintensity returned from the
deep white matter, generous extra-axial CSF spaces with bilateral and
symmetric underopercularization, and foreshortening and thinning
of an otherwise intact corpus callosum (Figure 1B). Previous genetic
testing included karyotyping for two affected siblings (II-4 and II-5)
and comparative genomic hybridization (CGH) for sibling (II-5) and
were nondiagnostic.
Family 2 is of Arab ancestry as well and consists of two affected
and two unaffected siblings born to a consanguineous union among
second cousins. The parents are healthy with an unremarkable family
history. Both female subjects were born at full term without neonatal
complications and were noted to have dysmorphic coarse facial fea-
tures, persisting hypotonia, and global developmental delay. Neuro-
ophthalmologic phenotype includes ataxia, dysarthria, and esotropia.
Additional common features amongboth siblingswere feeding difficul-
ties, delayed bone age, pectus carinatum, and mild scoliosis. The older
subject (II-3) was diagnosedwith ASD by echocardiogramwhereas the
younger subject (II-4) presented to the hospital at the age of 4 years
with fever and opsoclonus/myoclonus which settled after steroids
administration. MRI studies demonstrated irregular outline to the
bodies of both lateral ventricles in addition to the increased T2 hyper-
intensity returned from the periventricular white matter, and thinning
and foreshortening to the body of the corpus callosum. Karyotyping
and array CGH studies performed in the older subject were normal.
The proband (V:4) from Family 3 is a female born as result of the
first pregnancy to first cousin Iranian parents. Her dizygotic twin sis-
ter is healthy. The proband was referred for genetic testing at the
age of 8 months due to severe global developmental delays with
fronto-temporal pronounced thin cerebral cortex with enlarged outer
liquor spaces and enlarged lateral ventricles, thin corpus callosum, and
hypoplasia/atrophy of the optic nerve on brainMRI. Additional clinical
features included hypotonia, respiratory distress, slightly coarse facial
features, and hepatosplenomegaly. Family history showed that her
deceased first cousin (V:1) had a similar clinical presentation includ-
ing developmental delay/intellectual disability (IQ below 60), and oph-
thalmic features (strabismus, decreased visual acuity, and was blind
when she passed away at the age of 12 years). The proband as well as
the deceased affected cousin were not able to sit or walk. Addition-
ally, hypothyroidism was noted in both affected individuals as well as
somehealthy familymembers. Prior genetic testingwas not performed
in this family.
The proband from Family 4 is the first child born to consanguineous
Arabparents following anormal pregnancy.Hewasadmittedat the age
of 16 months to pediatric intensive care with an episode of decreased
consciousness and hypothermia, on a background of global devel-
opmental delay, hypotonia, and feeding difficulties. He had plagio-
cephaly, torticollis, slightly coarse facial features, and undescended
testes. Hewas smiling responsively, but unable to roll. MRI of the brain
demonstrated abnormally deep and box-like Sylvian fissures, diffuse
reduction in cerebral volume, particularly the deep white matter, dif-
fuse reduction in the brainstem and vermian volume, and dysmorphic
appearance of the corpus callosum and brainstem.
3.2 Identification of disease-causing variants
In order to establish theunderlying genetic cause,weperformedwhole
exome and whole genome sequencing in these four families. Analyses
ofWES andWGS data showed the proband in each of the four families
carried a homozygous truncating variant in the PPP1R21 gene, which
encodes a protein of unexplored function. Variant nomenclature pro-
vided here is based on RefSeq accession number NM_001135629.2.
In Family 1, we detected a deletion of one nucleotide c.347delT
p.(Ile116Lysfs*25) in exon 4 of PPP1R21. Subjects II-5 and II-6
are homozygous for c.347delT whereas their parents are obligate
carriers. Genotypes from additional family members cannot be
obtained because their DNA samples were not preserved before their
deaths due to disease (II-1 and II-4) or the accident (II-2 and II-3).
In Family 2, we found a homozygous insertion of four nucleotides
c.2170_2171insGGTA p.(Ile724Argfs*8) in exon 20 of PPP1R21 to co-
segregate with disease state in individuals II-3 and II-4. Both parents
are obligate carriers of the c.2170_2171insGGTA allele whereas the
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TABLE 2 Identified variants in the PPP1R21 gene
Family
Genomic
coordinates (hg19)
Variant nomenclature
(NM_001135629.2)
Zygosity and
variant type
Allele freq. in
ExAC
Allele freq. in
gnomAD
Family 1 chr2:48,685,338 c.347delT
p.(Ile116Lysfs*25)
Homozygous
frameshift
0.00 0.00
Family 2 chr2:48,737,238-
48,737,239
c.2170_2171insGGTA
p.(Ile724Argfs*8)
Homozygous
frameshift
0.00 0.00
Family 3 chr2:48,722,825 c.1607dupT
p.(Leu536Phefs*7)
Homozygous
frameshift
0.00 0.00
Family 4 chr2:48,734,502 c.2063delA
p.(Lys688Serfs*26)
Homozygous
frameshift
0.00 0.00
17DG0773a,b chr2:48,737,157 c.2089C>T p.(Arg697*) Homozygous
stop-gain
0.00 0.00
bChild 2 chr2:48,686,944 c.427C>T (p.Arg143*) Homozygous
stop-gain
0.00 0.000007
bChild 3 chr2:48,678,176_77 c.87_88delAG
(p.Gly30Cysfs*4)
Homozygous
frameshift
0.00 0.00
aFamily 17DG0773 is reported in Anazi et al. (2017).
bPatients reported by Suleiman et al. (2018).
ExAC and gnomADdatabases last accessed onMarch 29, 2018.
Freq; frequency, ExAC; Exome Aggregation Consortium, gnomAD; genomeAggregation Database.
two healthy siblings have at least one reference allele of PPP1R21. In
Family 3, probandV-4 is homozygous for duplication of onenucleotide,
c.1607dupT p.(Leu536Phefs*7), in exon 16 of PPP1R21 whereas her
healthy di-zygotic twin as well as remaining family members for
whom DNA is available are either heterozygous for c.1607dupT or
are homozygous for the reference allele (Figure 1A). In Family 4, the
proband is homozygous for deletion of one nucleotide, c. 2063delA
p.(Lys688Serfs*26), while the parents are heterozygous. All four trun-
cating variants are absent from ExAC (http://exac.broadinstitute.org)
and gnomAD (http://gnomad.broadinstitute.org) as well as from our
in-house database of approximately 10,000 clinical exomes. Addi-
tionally, no PPP1R21 homozygous loss of function variant is reported
in the ExAC or gnomAD databases suggesting that biallelic loss of
function variants in PPP1R21 are likely to cause a clinically detectable
phenotype. Clinical phenotypes of all affected individuals included in
this study (n = 6) as well as of three individuals reported in parallel to
our study by Suleiman et al. (2018) are displayed in Table 1. PPP1R21
variants identified to date are shown in Table 2.
3.3 Gene structure of PPP1R21
PPP1R21 resides on the short arm of chromosome 2 (2p16.3) and
consists of 22 protein coding exons. The NCBI reference sequence
database (RefSeq) lists three protein coding transcripts of human
PPP1R21 designated as transcript variant 1 (NM_001135629.2), 2
(NM_152994.4), and transcript variant 5 (NM_001193475.1). The
three transcripts have identical sequence content up to exon 15 and
differ in their sequence toward the 3′ end due to in-frame alternative
exon splicing (Figure 1C). Transcript variant 1 is the longest and codes
for 780 amino acids whereas transcript 2 lacks exon 18 (31 residues)
and transcript 5 lacks exons 16 and 18 (31+11 = 42 resides). All
protein truncating variants of PPP1R21 identified in patients affect the
three isoforms, except c.1607dupT p.(Leu536Phefs*7) that resides in
alternatively spliced exon 16 and affects isoforms 1 and 2 (functional
consequences of c.1607dupT in patient's fibroblasts are described
later in the article).
3.4 Protein structure and expression pattern of
PPP1R21
The PPP1R21 protein belongs to a family of predicted coiled-coil
domain containing proteins and its function has not been studied in
depth to date and no functional domains have been described. We
queried the NCBI database of nonredundant protein sequences (NCBI
BLAST: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) using
the longest isoform (NP_001129101.1) of PPP1R21 and found two
putative conserved domains within PPP1R21; an N-terminal KLRAQ
domain, and a C-terminal TTKRSYEDQ domain (Figure 1C). The pre-
dicted 100 amino acid long KLRAQ domain is encoded by residues
11–111 and contains a characteristic KLRAQ sequence-motif. The
500 amino acids long C-terminal TTKRSYEDQ domain is encoded by
residues 255–771 and has a characteristic TTKRSYEDQ sequence-
motif (Figure 1C). Both domains are conserved from nematodes to
humans but their molecular function(s) are yet to be discovered.
The Human Protein Atlas database (https://www.proteinatlas.org)
lists that PPP1R21 mRNA is expressed in a variety of tissues includ-
ing brain, endocrine, lungs, liver, heart, pancreas, spleen, and gastroin-
testinal tract. At the protein level, the strongest expression appears to
be in cerebellum, esophagus, pancreas, thyroid and parathyroid glands,
among others (Supp. Figure S2). We subsequently confirmed corti-
cal expression of PPP1R21 during murine development by perform-
ing immunofluorescence analysis onmouse E16 frozen cortex sections
using HPA036792, Atlas antibodies, Sweden) (Supp. Figure S3).
3.5 Subcellular localization of PPP1R21
Small cerebellum noted on the MRI and the phenotype observed in
some individuals with biallelic PPP1R21 loss of function mutations
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shows partially overlapping features with Joubert syndrome includ-
ing ataxic wide-based gait; further large-scale affinity-MS proteomics
analyses has previously suggested PPP1R21 to interact with a known
Joubert syndrome gene, PIBF1 (Huttlin et al., 2015; Wheway et al.,
2015b). This prompted us to next test the putative protein–protein
interaction between PPP1R21 and PIBF1 by co-immunoprecipitation.
Our tests could not confirm the interaction however (Supp. Figure
S4 and Supp. Figure S5) and subcellular immunofluorescence studies
in several cell lines such as hTERT-RPE (retinal pigment epithelium),
IMCD3 (inner medullary collecting duct), and the neuronal cell line
SH-SY5Y did not show ciliary or basal body or centrosomal PPP1R21
localization (Supp. Figure S6, 𝛼-acetylated tubulin (T7451, clone 6-11-
B) Sigma 1:500, 𝛼-PPP1R21). Rather, we observed a vesicular stain-
ing pattern within the cytosol of all tested cell lines which prompted
us to further investigate the nature of these vesicles by perform-
ing co-staining with antibodies for Golgi and endosomal marker pro-
teins. We did not detect co-localization of PPP1R21 with the two
Golgi markers that we tested (𝛼-58K; ab27043 from Abcam, and 𝛼-
GM130; ab169276, Abcam). However, we found a nearly complete
co-localization of PPP1R21 with the early endosome marker EEA1
(ab70521, mouse monoclonal, Abcam) using two different PPP1R21
antibodies, HPA036791 and HPA036792 (rabbit polyclonal, Atlas
antibodies, Sweden) (Figure 2A).
3.6 PPP1R21 expression is missing in patient
fibroblasts
qPCR analyses revealed that PPP1R21 mRNA levels are greatly
reduced in PPP1R21 deficient fibroblasts compared to control fibrob-
lasts (Supp. Figure S7) but not completely absent. We, therefore,
proceeded to perform immunofluorescence analysis to examine
protein levels and localization in mutant cells versus control cell
lines: as expected here we found that in 2 lines of human control
fibroblasts, PPP1R21 consistently co-localized with early endo-
some marker EEA1. However, this staining pattern was absent from
fibroblasts of individual V:4 who is homozygous for the PPP1R21
c.1607dupT p.(Leu536Phefs*7) allele, proving specificity of both
PPP1R21 antibodies and demonstrating the variant results in a true
null allele (Figure 2B). EEA1 staining did not differ between PPP1R21
deficient and control cells, indicating PPP1R21 is not required for
EEA1 localization. A weak nuclear staining pattern for PPP1R21 was
still detected by immunofluorescence in PPP1R21 mutant cells, this
could indicate that low levels of protein localizing to the nucleus is
still present in patient cells but it is also possible the nuclear staining
pattern observed in mutant and wildtype cells is nonspecific and
truncated PP1R21 protein, if translated from the remaining low levels
of RNA, is subjected to proteasomal degradation.
3.7 Uptake and clearance of transferrin-488 in
PPP1R21mutant fibroblasts
Clinical features observed in patients with PPP1R21 variants, such
as thin fronto-temporal cortex with enlarged external liquor spaces
in combination with coarse face, hepatosplenomegaly, and vision
impairment, reminded us of the clinical picture observed in patients
with inborn errors of metabolism such as Morbus Gaucher (Roshan
Lal & Sidransky, 2017) or other neurometabolic/lysosomal (storage)
diseases (Karimzadeh, 2015). This in combination with our subcellu-
lar localization studies suggesting PPP1R21 resides within the early
endosome prompted us to next study uptake and clearance of fluo-
rescence labelled transferrin (transferrin-488) in control fibroblasts as
well as fibroblasts from patient V:4 (Family 3). We found unchanged
transferrin uptake in fibroblasts of an affected individual with defi-
nite PPP1R21 loss of function compared to control fibroblasts, indi-
cating macro-autophagy is not disturbed by PPP1R21 dysfunction
and/or transferrin uptake may take place by receptor mediated endo-
cytosis which is likewise intact. However, interestingly, transferrin-
488 clearance was mildly but statistically significantly delayed in the
PPP1R21mutant cells (p= 0.0015, Student's t-Test) after 2 hr of repet-
itive washes with medium containing unlabeled transferrin (“chase”)
(Figure 3 and Supp. Figure S8).
3.8 Increased number ofmyelin figures in PPP1R21
deficient fibroblasts confirmingmild endo-lysosomal
dysfunction
Our immunofluorescence data as well as the transferrin uptake and
clearance assay suggested PPP1R21 locates to the early endosome
and that patient fibroblasts exhibit mild endo-lysosomal dysfunction.
To assess if this defect results in abnormal storage of cellular material
within cytoplasmic vesicles, we next performed electron microscopy
(EM) analyses using PPP1R21 deficient fibroblasts as well as two
control fibroblast lines. This revealed mildly increased number of
myelin figures/myelin bodies in fibroblasts of patient V:4 carrying
homozygous c.1607dupT p.(Leu536Phefs*7) variant in PPP1R21while
no myelin figures/myelin bodies were observed in the control lines
(Figure 4).
4 DISCUSSION
This study identified four previously unreported homozygous
truncating alleles of PPP1R21 co-segregating in four independent
consanguineous families with affected individuals exhibiting overlap-
ping clinical features. Consistent with our findings, a female subject
homozygous for a PPP1R21 null allele was recently described within
a larger cohort of developmental delay cases (Anazi et al., 2017). Her
reported clinical presentation was very similar to what we observed in
families 1–4 inour study including slightly coarseneddysmorphic facial
features, severe global developmental delays, hypotonia, respiratory
distress, feeding difficulties, hepatomegaly, and vision impairment.
During preparation of this manuscript, two additional subjects with
homozygous putative PPP1R21 null alleles have been described
(Suleiman et al., 2018).We have summarized common clinical features
observed among all nine subjects (six from this study and three pre-
viously reported (Anazi et al., 2017; Suleiman et al., 2018) in Table 1:
most commonly observed features include hypotonia (9/9), severe
global developmental delays (9/9), dysmorphic mildly coarsened facial
features (9/9), vision impairment and/or nystagmus (8/9), respiratory
problems (n = 7/9), feeding difficulties (n = 9/9), cardiac concerns
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F IGURE 2 PPP1R21 co-localizes with themain early endosome protein EEA1 but not Golgi proteins and PPP1R21 staining is absent in
fibroblasts obtained from patient 3_V:4 who is homozygous for c.1607dupT p.(Leu536Phefs*7). (A) In order to determine the entity of PPP1R21
positive vesicles, we performed co-localization studies using Golgi marker GM130 (mouse, ab169276, Abcam, USA) and 58K (ab27043mouse,
Abcam, USA) as well as EEA1 antibody tomark the early endosome.While no co-localization with Golgi markers was observed (upper panels),
PPP1R21 (rabbit, HPA036792, Atlas antibodies, Sweden) nearly completely co-localized with EEA1 (lower panel). Scale bar 20 𝜇m. (B)Using two
different PPP1R21 antibodies, HPA036792 (ab1, antibody epitope is represented by aminoacid aa161-256) andHPA 036791 (ab2, antibody
epitope is represented by aminoacid aa572-666), we found complete loss of the vesicular staining pattern in PPP1R21mutant fibroblasts we
previously observed in control cells while no difference regarding EEA1 staining was detected between PPP1R21mutant and control fibroblasts.
Scale bar: 20 𝜇m
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F IGURE 3 Transferrin-488 uptake and clearance in PPP1R21mutant fibroblasts and control cells. (A) Representative images of transferrin-488
uptake and clearance in PPP1R21mutant fibroblasts (lower panel) and control cells (upper panel) taken after 5 and 30min of transferrin-488
exposure and 1 and 2 hr of transferrin-488washout (chase). Scale bar= 30 𝜇m. (B) Quantification of transferrin-488 uptake 5 and 30min after
exposure to supplementedmedium and 1 and 2 hr of washout (chase, exposure tomediumwhere transferrin-488was replacedwith unlabeled
transferrin and renewal of themedium every 20min).While the number of transferrin-488 positive cells did not differ significantly between
PPP1R21mutant and control fibroblasts after 5 and 30min or after 1 hr of chase, more cells were positive after 2 hr of chase, with a strong
statistical significance (p= 0.0015, Student's t-test). Control cells are shown in dark grey andmutant cells in light grey
F IGURE 4 Increased number of myelin figures in PPP1R21 deficient fibroblasts confirmingmild endo-lysosomal dysfunction. Electron
microscopy (EM) revealedmildly increased number of myelin figures/myelin bodies in fibroblasts of patient V:4 carrying homozygous c.1607dupT
p.(Leu536Phefs*7) variant of PPP1R21. We observed 1–2myelin bodies per vision field (arrows). These figures were not observed in two
fibroblast control cell lines cultured in parallel. Scale bar: 500 nm
(n= 4/9), and hepato/hepatosplenomegaly (n= 3/7; Table 1). Common
findings onMRI of the brain include prominent and slightly dysmorphic
ventricular system with irregular outline to the bodies of the lateral
ventricles reminiscent of PVL (periventricular leukomalacia) and
consistent with loss of white matter (Figure 1B and Table 1). There is
some increased T2 hyperintensity returned from the deep white mat-
ter in all cases (where images were available). Further, generous extra-
axial CSF spaces with bilateral and symmetric underopercularization
as well as slight foreshortening and thinning of the corpus callosum
was noted as well as cerebellar hypoplasia in some but not all cases.
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PPP1R21 is an evolutionarily conserved protein (Supp. Figure
S9) with an undiscovered function and no investigations toward
understanding the underlying patho-mechanism had been performed.
This prompted us to perform functional analysis to gain insight into
the physiological role of PPP1R21 and to identify possible disease
mechanism for the observed PPP1R21-associated phenotype. Consis-
tent with the severe neurodevelopmental phenotype observed, our
immunofluorescence studies confirmed PPP1R21 expression within
the developing mouse cortex (Supp. Figure S3). A large-scale pro-
teomics study had previously suggested PPP1R21 may interact with
PIBF1, a protein found to be defective in some individualswith Joubert
syndrome (Huttlin et al., 2015; Wheway et al., 2015a). However, our
co-immunoprecipitation analyses did not confirm the suggested inter-
action (Supp. Figure S4). Rather, using two different antibodies, we
observed nearly complete co-localization of PPP1R21 with the early
endosome marker EEA1 (Figure 2A) and transferrin-488 uptake and
clearance assays (Figure3) suggested amild endo-lysosomal functional
defect. We found that although there was no difference of transferrin
uptake between control and patient fibroblasts, its clearance was
mildly but statistically significantly delayed in the PPP1R21 mutant
cells after 2 hr of repetitive washes with medium containing unlabeled
transferrin (“chase”). This could indicate a mild endosome maturation
or fusion defect or could result from a trafficking defect back toward
the plasma membrane. Such impaired proteolipid protein trafficking
has been previously described to result from cathepsin D deficiency
where phenotypically delayed central nervous systemmyelinationwas
observed (Guo et al., 2018; Steinfeld et al., 2006) and hypomyelination
was also noted in the brain MRI scans in Family 1 described here.
However, PPP1R21 localization to early endosomes differs from
cathepsin D localization to late endosomes/lysosomes, rendering
such a retrograde trafficking defect as an unlikely major cause for the
observed phenotype. Our EM studies confirmed mild endo-lysosomal
dysfunction in patient fibroblasts in comparison to control cell lines
with a mildly increased number of myelin figures/myelin bodies
observed in the PPP1R21 loss of function cell line (Figure 4).
The dynamics of the endocytic pathways are governed by several
Rab family members with Rab 5 playing a major role in the early
endosome traffic (Barbieri, Roberts, Mukhopadhyay, & Stahl, 1996;
Murray, Panaretou, Stenmark, Miaczynska, & Backer, 2002). Some
phenotypic features observed in the affected familiesmay also directly
result from Protein Phosphatase 1 (PP1) dysfunction. PP1 is a major
serine/threonine phosphatase with an immense diversity of functions,
including fundamental processes suchas glycogenmetabolism (Munro,
Cuthbertson, Cunningham, Sales, &Cohen, 2002), cell cycle regulation,
and regulation of centriole duplication (Peel et al., 2017), apoptosis
(Garcia et al., 2003), and PP1 is expressed during development in
murine brains (Collins & Sim, 1998). PP1 consists of a catalytic subunit
(PPP1CA) and a high number of regulatory subunit determining the
subcellular localization of PP1 and regulating its function. Future work
will be required to further investigate this area.
Although previously published large scale proteomics data sug-
gested an interaction with the Joubert protein PIBF1, patient phe-
notype did not match Joubert syndrome or related ciliopathies and
our co-immunoprecipitation studies and the subcellular localization to
early endosomes in several cell lines points against a role within the
Joubert syndrome protein network. Rather, our results point toward
a defect within the endosomal-lysosomal compartment, as it has been
previously suggested for other neurodegenerative diseases in humans,
resulting in an endocytic defects or impaired clearance of certain
molecules from this compartment. For example, a phenotype some-
what resembling the phenotype we observe with PPP1R21 loss of
function including coarse face, neurodevelopmental delay, and cere-
bellar atrophy was described to result from SNX14 (sorting nexin 14)
loss of function mutations (Akizu et al., 2015; Thomas et al., 2014).
SNX proteins are known to play a role in endosomal cargo sort-
ing and SNX14 was shown to be essential for fusion of late endo-
some/autophagosomeswith lysosomal vesicles in fibroblasts aswell as
neuronal precursor cells from individuals (Akizu et al., 2015).
In conclusion, we propose recessive PPP1R21 loss of function vari-
ants as a cause of a distinct neurodevelopmental syndrome with fea-
tures of mild endosomal-lysosomal dysfunction. All identified variants
have protein-truncating properties and studies in fibroblasts of one
affected individual reveal complete absence of PPP1R21 protein. We
further show that PPP1R21 co-localizes with EEA1 in early endo-
somes and loss of PPP1R21 results in a mild transferrin clearance
defect in PPP1R21null-fibroblasts, indicating PPP1R21 is essential for
proper functioning of the early endosome compartment. Future stud-
ies including appropriate animal models are warranted to understand
the precise molecular mechanism that leads to PPP1R21-associated
neurodevelopmental phenotype.
ACKNOWLEDGMENTS
Wethank the subjects and their families formaking this study possible.
We thankProf. H.Omran,Munster, Germany, for evaluation of theMRI
of Family 3 individual V-4 and Thilo Bass, Freiburg, Germany for excel-
lent technical assistance. We also thank Elizabeth A. Normand for her
support.
COMPETING INTERESTS
The Department of Molecular and Human Genetics at the Baylor
College of Medicine derives revenue from molecular genetic testing
offered at the BaylorMiraca Genetics Laboratories.
PATIENT CONSENT
Obtained.
ETHICAL APPROVAL
The study was approved by respective ethics committees from Baylor
College of Medicine in USA, Sidra Medicine in Qatar, University
of Geneva in Switzerland, the Innovative diagnostics programme,
Radboudumc Nijmegen, the Netherlands, and the Royal Children's
Hospital, Melbourne.
ORCID
Lihadh Al-Gazali https://orcid.org/0000-0003-2029-2218
Miriam Schmidts https://orcid.org/0000-0002-1714-6749
280 REHMAN ET AL.
REFERENCES
Akizu, N., Cantagrel, V., Zaki, M. S., Al-Gazali, L., Wang, X., Rosti, R. O., …
Gleeson, J. G. (2015). Biallelic mutations in SNX14 cause a syndromic
form of cerebellar atrophy and lysosome-autophagosome dysfunction.
Nature Genetics, 47(5), 528–534. https://doi.org/10.1038/ng.3256
Anazi, S., Maddirevula, S., Salpietro, V., Asi, Y. T., Alsahli, S., Alhashem,
A., … Alkuraya, F. S. (2017). Expanding the genetic heterogeneity of
intellectual disability.HumanGenetics,136(11–12), 1419–1429. https://
doi.org/10.1007/s00439-017-1843-2
Barbieri, M. A., Roberts, R. L., Mukhopadhyay, A., & Stahl, P. D. (1996). Rab5
regulates the dynamics of early endosome fusion. Biocell, 20(3), 331–
338.
Bennett, M. J., & Hofmann, S. L. (1999). The neuronal ceroid-lipofuscinoses
(Batten disease): A new class of lysosomal storage diseases. Journal of
InheritedMetabolic Disease, 22(4), 535–544.
Boycott, K.M., Rath,A., Chong, J. X.,Hartley, T., Alkuraya, F. S., Baynam,G.,…
Lochmuller,H. (2017). International cooperation toenable thediagnosis
of all rare genetic diseases. American Journal of Human Genetics, 100(5),
695–705. https://doi.org/10.1016/j.ajhg.2017.04.003
Chong, J. X., Buckingham, K. J., Jhangiani, S. N., Boehm, C., Sobreira, N.,
Smith, J. D., … Bamshad, M. J. (2015). The genetic basis of Mendelian
phenotypes: Discoveries, challenges, and opportunities. American
Journal of Human Genetics, 97(2), 199–215. https://doi.org/10.1016/
j.ajhg.2015.06.009
Collins, E., & Sim, A. T. (1998). Regulation of neuronal PP1 and PP2A
during development. Methods in Molecular Biology, 93, 79–102.
https://doi.org/10.1385/0-89603-468-2:79
Fuller, M., Meikle, P. J., & Hopwood, J. J. (2006). Epidemiology of lysoso-
mal storage diseases: An overview. In A. Mehta, M. Beck, & G. Sunder-
Plassmann (Eds.), Fabry Disease: Perspectives from 5 Years of FOS. Oxford:
Oxford PharmaGenesis.
Garcia, A., Cayla, X., Guergnon, J., Dessauge, F., Hospital, V., Rebollo, M. P.,
… Rebollo, A. (2003). Serine/threonine protein phosphatases PP1 and
PP2A are key players in apoptosis. Biochimie, 85(8), 721–726.
Guo, D. Z., Xiao, L., Liu, Y. J., Shen, C., Lou, H. F., Lv, Y., & Pan, S. Y. (2018).
Cathepsin D deficiency delays central nervous system myelination by
inhibiting proteolipid protein trafficking from late endosome/lysosome
to plasma membrane. Experimental Molecular Medicine, 50(3), e457.
https://doi.org/10.1038/emm.2017.291
Huttlin, E. L., Ting, L., Bruckner, R. J., Gebreab, F., Gygi, M. P., Szpyt, J., …
Gygi, S. P. (2015). The BioPlex network: A systematic exploration of
the human interactome.Cell,162(2), 425–440. https://doi.org/10.1016/
j.cell.2015.06.043
Jovic, M., Sharma, M., Rahajeng, J., & Caplan, S. (2010). The early endo-
some:Abusy sorting station for proteins at the crossroads.Histology and
Histopathology, 25(1), 99–112. doi: 10.14670/HH-25.99
Karimzadeh, P. (2015). Approach to neurometabolic diseases from a pedi-
atric neurological point of view. Iranian Journal of Child Neurology, 9(1),
1–16.
Maxfield, F. R. (2014). Role of endosomes and lysosomes in human
disease. Cold Spring Harbor Perspectives in Biology, 6(5), a016931.
https://doi.org/10.1101/cshperspect.a016931
Munro, S., Cuthbertson,D. J., Cunningham, J., Sales,M.,&Cohen,P. T. (2002).
Human skeletal muscle expresses a glycogen-targeting subunit of PP1
that is identical to the insulin-sensitive glycogen-targeting subunit G(L)
of liver.Diabetes, 51(3), 591–598.
Murray, J. T., Panaretou, C., Stenmark, H., Miaczynska, M., & Backer,
J. M. (2002). Role of Rab5 in the recruitment of hVps34/p150
to the early endosome. Traffic (Copenhagen, Denmark), 3(6), 416–
427.
Parkinson-Lawrence, E. J., Shandala, T., Prodoehl, M., Plew, R., Borlace, G.
N., & Brooks, D. A. (2010). Lysosomal storage disease: Revealing lysoso-
mal function and physiology. Physiology (Bethesda, MD), 25(2), 102–115.
https://doi.org/10.1152/physiol.00041.2009
Peel, N., Iyer, J., Naik, A., Dougherty, M. P., Decker, M., & O'Connell,
K. F. (2017). Protein phosphatase 1 down regulates ZYG-1 levels to
limit centriole duplication. PLoS Genetics, 13(1), e1006543. https://
doi.org/10.1371/journal.pgen.1006543
Platt, F. M., Boland, B., & van der Spoel, A. C. (2012). The cell biology of
disease: Lysosomal storage disorders–The cellular impact of lysosomal
dysfunction. Journal of Cell Biology, 199(5), 723–734. https://doi.org/
10.1083/jcb.201208152
Roshan Lal, T., & Sidransky, E. (2017). The spectrum of neurologi-
cal manifestations associated with Gaucher disease. Diseases, 5(1).
https://doi.org/10.3390/diseases5010010
Schmidts, M., Hou, Y., Cortes, C. R., Mans, D. A., Huber, C., Boldt, K.,…Wit-
man, G. B. (2015). TCTEX1D2 mutations underlie Jeune asphyxiating
thoracic dystrophy with impaired retrograde intraflagellar transport.
Nature Communications, 6, 7074. https://doi.org/10.1038/ncomms8074
Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R.,
Bruck, W., … Gartner, J. (2006). Cathepsin D deficiency is associated
with a human neurodegenerative disorder. American Journal of Human
Genetics, 78(6), 988–998. https://doi.org/10.1086/504159
Suleiman, J., Al Hashem, A. M., Tabarki, B., Al-Thihli, K., Bi, W., & El-
Hattab, A. W. (2018). PPP1R21 homozygous null variants associated
with developmental delay, muscle weakness, distinctive facial fea-
tures, and brain abnormalities. Clinical Genetics, 94(3–4), 351–355.
https://doi.org/10.1111/cge.13387
Thomas, A. C., Williams, H., Seto-Salvia, N., Bacchelli, C., Jenkins, D.,
O'Sullivan, M., … Stanier, P. (2014). Mutations in SNX14 cause a dis-
tinctive autosomal-recessive cerebellar ataxia and intellectual disabil-
ity syndrome. American Journal of Human Genetics, 95(5), 611–621.
https://doi.org/10.1016/j.ajhg.2014.10.007
Wheway, G., Schmidts, M., Mans, D. A., Szymanska, K., Nguyen, T.
M., Racher, H., … Johnson, C. A. (2015a). An siRNA-based func-
tional genomics screen for the identification of regulators of cilio-
genesis and ciliopathy genes. Nature Cell Biology, 17(8), 1074–1087.
https://doi.org/10.1038/ncb3201
Wheway, G., Schmidts, M., Mans, D. A., Szymanska, K., Nguyen, T.
T., Racher, H., … Johnson, C. A. (2015b). An siRNA-based func-
tional genomics screen for the identification of regulators of cilio-
genesis and ciliopathy genes. Nature Cell Biology, 17(8), 1074–1087.
https://doi.org/10.1038/ncb3201
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: Rehman AU, Najafi M, Kambouris M,
et al. Biallelic loss of function variants in PPP1R21 cause a neu-
rodevelopmental syndrome with impaired endocytic function.
Human Mutation. 2019;40:267–280. https://doi.org/10.1002/
humu.23694
